GLUE vs. PSTX, CADL, IVVD, ADAP, STRO, AVXL, FENC, CHRS, SOPH, and AGEN
Should you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Poseida Therapeutics (PSTX), Candel Therapeutics (CADL), Invivyd (IVVD), Adaptimmune Therapeutics (ADAP), Sutro Biopharma (STRO), Anavex Life Sciences (AVXL), Fennec Pharmaceuticals (FENC), Coherus BioSciences (CHRS), SOPHiA GENETICS (SOPH), and Agenus (AGEN). These companies are all part of the "biological products, except diagnostic" industry.
Poseida Therapeutics (NASDAQ:PSTX) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, community ranking, risk and institutional ownership.
Poseida Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.
46.9% of Poseida Therapeutics shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 2.1% of Poseida Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Poseida Therapeutics has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Poseida Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Monte Rosa Therapeutics had 3 more articles in the media than Poseida Therapeutics. MarketBeat recorded 6 mentions for Monte Rosa Therapeutics and 3 mentions for Poseida Therapeutics. Poseida Therapeutics' average media sentiment score of 0.80 beat Monte Rosa Therapeutics' score of 0.22 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.
Poseida Therapeutics currently has a consensus price target of $14.67, indicating a potential upside of 425.69%. Monte Rosa Therapeutics has a consensus price target of $11.00, indicating a potential upside of 118.25%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Poseida Therapeutics is more favorable than Monte Rosa Therapeutics.
Monte Rosa Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -190.76%. Poseida Therapeutics' return on equity of -74.13% beat Monte Rosa Therapeutics' return on equity.
Poseida Therapeutics received 24 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 64.71% of users gave Poseida Therapeutics an outperform vote while only 37.50% of users gave Monte Rosa Therapeutics an outperform vote.
Summary
Poseida Therapeutics beats Monte Rosa Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Monte Rosa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monte Rosa Therapeutics Competitors List
Related Companies and Tools
